Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody

International Journal of Cancer

Volumn 122, Issue 10, 2008, Pages 2310-2314

  Stollman, Thamar H ^a   Scheer, Marian G W ^a   Leenders, William P J ^a   Verrijp, Kiek C N ^a   Soede, Annemieke C ^a   Oyen, Wim J G ^a   Ruers, Theo J M ^b   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Angiogenesis; Bevacizumab; Colorectal cancer; Scintigraphy; VEGF

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; BEVACIZUMAB I 125; BEVACIZUMAB IN 111; ISOPROTEIN; MONOCLONAL ANTIBODY; RADIOISOTOPE; UNCLASSIFIED DRUG; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; DIAGNOSTIC AGENT; INDIUM; MESSENGER RNA; RADIOACTIVE IODINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; IMAGING SYSTEM; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; SCINTIGRAPHY; SCINTILLATION CAMERA; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COLON TUMOR; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTISCANNING; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42149169958     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23404     Document Type: Article

References (19)

1. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
3. Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F, Ellis LM. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer 2005;103:1561-70.
4. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
5. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004;350:2406-8.
6. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
7. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
8. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
9. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
10. Hnatowich DJ, Childs RL, Lanteigne D, Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods 1983;65:147-57.
11. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 2004;45:327-37.
12. Uemura H, Okajima E, Debruyne FM, Oosterwijk E. Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer 1994;56:609-14.
13. Roodink I, van der LJ, Kusters B, Wesseling P, Verrijp K, de WR, Leenders W. Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 2006;119:2054-62.
14. van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride BJ, Goldenberg DM, Corstens FH, Boerman OC. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med 2005;46:1016-22.
15. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
16. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996;93:1493-5.
17. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-7.
18. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26.
19. Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli MP, Rossi C, Baldelli AM, Grianti C, Muretto P, Catalano G. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001;12:239-44.